BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that it has appointed experienced life sciences executive Anna Tenstam to the role of vice president of business development, cosmeceuticals and injectables to propel the expansion of its recently launched Contract Development and Manufacturing Organization (CDMO) services business unit.
The company said that Tenstam brings more than 30 years of leadership experience with pharmaceutical, medical devices and medical aesthetics companies worldwide to the position.
She has managed global brands and been involved with several license and exit deals with companies, including Colbar Lifescience/J&J, and Q-MED/Medicis/Galderma, it highlighted.
"Anna's business development acumen, paired with her extensive experience in life sciences, presents an incredible opportunity to accelerate our business with pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders," BioHarvest Sciences CEO Ilan Sobel said in a statement.
"Her invaluable relationships with global industry partners within these industries positions BioHarvest to attract development and long-term manufacturing contracts for our CDMO business unit. We look forward to working closely with Anna going forward as we continue to successfully scale operations, all with the goal of creating sustainable value for my fellow shareholder partners over the long term."
Tenstam, meanwhile, said she was excited to join the BioHarvest Sciences team, where she will focus on building partnerships with industry leaders who are searching for the next generation of therapeutic molecules.
“My chief focus at BioHarvest will be to uncover new opportunities within cosmeceuticals and injectables, with the goal of building revenues for the CDMO services business unit,” she said.
BioHarvest Sciences is a leader in botanical synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant.